NCT00733863View on ClinicalTrials.gov

Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

February 28, 2010

Conditions
Alzheimer Disease
Interventions
BIOLOGICAL

Placebo

BIOLOGICAL

CAD106

Trial Locations (4)

Unknown

Centre Hospitalier Universitaire Pellegrin, Bordeaux

Karolinska Universitetssjukhuset Huddinge, Stockholm

NeuroPsychologieZentrum, Basel

Moorgreen Hospital, Southampton

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00733863 - Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients. | Biotech Hunter | Biotech Hunter